Global strategies and actions to eliminate hepatitis B virus infection
Clinical and Molecular Hepatology · 01.10.2025 · 31 (4) · 1197-1212
DOI: 10.3350/cmh.2025.0492 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2025. Verfasst von Chih-Lin Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Renai Branch, Taipei City Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Taiwan University Hospital, Ministry of Health and Welfare, National Science and Technology Council, Executive Yuan, Taiwan.
Abstract (Originalsprache)
Through the implementation of hepatitis B vaccination and effective antiviral treatment over the past four decades, the hepatitis B surface antigen (HBsAg) seroprevalence of the vaccinated generation dramatically decline. The incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) also decreases. However, the elimination of HBV is still a challenge to achieve. Novel HBV biomarkers, including quantitative HBsAg, hepatitis B virus core-related antigen and HBV RNA are promising in predicting clinical phases, risks of disease progression and HBV functional cure. Current antiviral therapies, nucleoside/nucleotide and pegylated alpha-interferon, effectively decrease HCC incidence in chronic hepatitis B (CHB) patients and minimize the recurrence of HCC in patients receiving curative therapy. Novel agents under development to achieve HBV cure include direct-acting antivirals that target various stages of the HBV lifecycle and host targeting agents that enhance HBV-specific immunity. The action plans for eliminating hepatitis B in the future are universal HBV screening, early and simplified treatment as well as precision lifelong management for CHB patients. This narrative review will summarize and discuss global strategies and initiatives aimed at eliminating HBV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Renai Branch, Taipei City Hospital, Taipei, Taiwan.
- Department of Psychology, National Chengchi University, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, National Taiwan University, College of Medicine, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Research, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan.
Förderung
- National Taiwan University Hospital
- Ministry of Health and Welfare
- National Science and Technology Council, Executive Yuan, Taiwan
Zitieren
APA
Lin, C. L., & Kao, J. H. (2025). Global strategies and actions to eliminate hepatitis B virus infection. Clinical and Molecular Hepatology, 31(4), 1197-1212. https://doi.org/10.3350/cmh.2025.0492
Vancouver
Lin CL, Kao JH. Global strategies and actions to eliminate hepatitis B virus infection. Clinical and Molecular Hepatology. 2025;31(4):1197-1212. doi:10.3350/cmh.2025.0492
BibTeX
@article{Lin2025,
author = {Lin, Chih-Lin and Kao, Jia-Horng},
title = {Global strategies and actions to eliminate hepatitis B virus infection},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {4},
pages = {1197--1212},
doi = {10.3350/cmh.2025.0492}
}
EUVIMED